Nippon Kayaku To Increase Sales Five-fold Through Intravascular Cancer Drugs
This article was originally published in PharmAsia News
Nippon Kayaku has prioritized cancer treatment through vascular injection as the new growth area, aiming to increase its sales five-fold to ¥10 billion by 2016 through new product launches
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.